StocksMedium•5 November 2026•
1 min read
LifeMD Partners with Eli Lilly to Distribute GLP-1 Weight Loss Medications
Key Facts
1LifeMD announced a collaboration with Eli Lilly to facilitate the dispensing of GLP-1 weight loss medications.
LifeMD announced a collaboration with Eli Lilly to facilitate the dispensing of GLP-1 weight loss medications. Investing.com reported that the partnership aims to integrate the pharmaceutical giant's treatments into LifeMD's digital healthcare infrastructure.
LFMD closed at $2.45 on November 4, 2026, with the stock reaching a day high of $2.48 and a low of $2.24 during that session. This strategic move positions the telehealth firm to capitalize on the high-growth GLP-1 market by streamlining patient access through its digital platform.